- Home
- DRIO vs MREO Comparison
DRIO vs MREO Comparison
Compare DRIO & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DRIO | MREO |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.8M | 67.5M |
| IPO Year | 2013 | 2017 |
Fundamental Metrics
Financial Performance| Metric | DRIO | MREO |
|---|---|---|
| Price | $8.42 | $0.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $60.00 | $3.90 |
| AVG Volume (30 Days) | 7.7K | ★ 1.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 9.05 | N/A |
| Revenue | ★ $7,394,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.15 | $6,363.05 |
| P/E Ratio | $0.99 | ★ N/A |
| Revenue Growth | ★ 43.02 | N/A |
| 52 Week Low | $0.38 | $0.20 |
| 52 Week High | $17.74 | $2.94 |
Technical Indicators
Market Signals| Indicator | DRIO | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 34.60 | 42.00 |
| Support Level | $0.56 | $0.35 |
| Resistance Level | $12.36 | $0.45 |
| Average True Range (ATR) | 0.62 | 0.03 |
| MACD | -0.16 | 0.02 |
| Stochastic Oscillator | 18.74 | 70.30 |
Price Performance
Historical ComparisonAbout DRIO DarioHealth Corp.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).